160 related articles for article (PubMed ID: 25132887)
1. Hyperlipidemia medication management in patients admitted for a myocardial infarction.
Shuster JE; Jeffres MN; Barclay SM; Bhakta R
Pharm Pract (Granada); 2011 Jan; 9(1):31-6. PubMed ID: 25132887
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
4. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
[TBL] [Abstract][Full Text] [Related]
5. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
6. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE
J Am Coll Cardiol; 2013 Oct; 62(17):1580-4. PubMed ID: 23916935
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein apheresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
[TBL] [Abstract][Full Text] [Related]
8. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
[TBL] [Abstract][Full Text] [Related]
9. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
McKenney JM; Jones PH; Bays HE; Knopp RH; Kashyap ML; Ruoff GE; McGovern ME
Atherosclerosis; 2007 Jun; 192(2):432-7. PubMed ID: 17239888
[TBL] [Abstract][Full Text] [Related]
11. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Alrasadi K; Awan Z; Alwaili K; Ruel I; Hafiane A; Krimbou L; Genest J
Am J Cardiol; 2008 Nov; 102(10):1341-7. PubMed ID: 18993152
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in lipid profiles and treatment utilization among young adults with acute myocardial infarction: Results from the VIRGO study.
Lu Y; Zhou S; Dreyer RP; Caulfield M; Spatz ES; Geda M; Lorenze NP; Herbert P; D'Onofrio G; Jackson EA; Lichtman JH; Bueno H; Spertus JA; Krumholz HM
Am Heart J; 2017 Jan; 183():74-84. PubMed ID: 27979045
[TBL] [Abstract][Full Text] [Related]
14. Elevated Serum Non-HDL (High-Density Lipoprotein) Cholesterol and Triglyceride Levels as Residual Risks for Myocardial Infarction Recurrence Under Statin Treatment.
Suzuki K; Oikawa T; Nochioka K; Miura M; Kasahara S; Sato M; Aoyanagi H; Shiroto T; Takahashi J; Miyata S; Sakata Y; Shimokawa H
Arterioscler Thromb Vasc Biol; 2019 May; 39(5):934-944. PubMed ID: 30866657
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of lipoprotein indices for residual risk of acute myocardial infarction and sudden death in men with low-density lipoprotein cholesterol levels <120 mg/dl.
Tanaka F; Makita S; Onoda T; Tanno K; Ohsawa M; Itai K; Sakata K; Omama S; Yoshida Y; Ogasawara K; Ogawa A; Ishibashi Y; Kuribayashi T; Okayama A; Nakamura M;
Am J Cardiol; 2013 Oct; 112(8):1063-8. PubMed ID: 23831165
[TBL] [Abstract][Full Text] [Related]
16. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W
N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343
[TBL] [Abstract][Full Text] [Related]
17. Myocardial infarction in young adults with low-density lipoprotein cholesterol levels < or = 100 mg/dL: clinical profile and 1-year outcomes.
Akosah KO; Cerniglia RM; Havlik P; Schaper A
Chest; 2001 Dec; 120(6):1953-8. PubMed ID: 11742927
[TBL] [Abstract][Full Text] [Related]
18. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
[TBL] [Abstract][Full Text] [Related]
20. Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGHÂ trial.
Toth PP; Jones SR; Slee A; Fleg J; Marcovina SM; Lacy M; McBride R; Boden WE
J Clin Lipidol; 2018; 12(3):741-747.e11. PubMed ID: 29627296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
